Clinical trials: Essential Hypertension.
Hypertension
Trial of Telmisartan 80 mg/HCTZ 12.5 mg and Telmisartan 40 mg/HCTZ 12.5 mg in Patients With Hypertension
The objective of this trial is to assess the safety and efficacy of 52 weeks of open-label treatment with the fixed dose combination of telmisartan 80 mg plus HCTZ 12.5 mg and telmisartan 40 mg plus HCTZ 12.5 mg in patients with…
- Trial name
- NCT00326768
- Testing
- Telmisartan 40 mg/HCTZ 12.5 mg, Telmisartan 40 mg, Telmisartan 80 mg/HCTZ 12.5 mg
- Where
- 3 sites in Japan
- Volunteers
- 184 people
- Sponsor
- Boehringer Ingelheim
Hypertension
Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension
The purpose of this study is to compare the efficacy and safety of TAK-491 (azilsartan medoxomil), once daily (QD), to valsartan in participants with essential hypertension.
- Trial name
- NCT00591578
- Testing
- Azilsartan Medoxomil, Valsartan
- Where
- 88 sites in United States, Chile and 2 more
- Volunteers
- 984 people
- Sponsor
- Takeda
Essential Hypertension
A Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension
The objective of this clinical trial is to evaluate the antihypertensive efficacy and safety of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 with essential hypertension.
- Trial name
- NCT07373613
- Testing
- BR1400-1, BR1400-2, BR1400-3
- Where
- South Korea
- Volunteers
- 330 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
CKD-828 (40/5mg) Pharmacokinetic Study
The purpose of this study is to evaluate the pharmacokinetic characteristics of CKD-828 (Fixed Dose Combination Tablet; Telmisartan and S-Amlodipine) in healthy volunteer.
- Trial name
- NCT01340131
- Testing
- CKD-828, Combination Therapy
- Where
- South Korea
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Essential Hypertension
Amlodipine as add-on to Olmesartan in Hypertension
Test the efficacy and safety of the combination of olmesartan and amlodipine in hypertensive patients whose blood pressure is not adequately controlled with olmesartan alone.
- Trial name
- NCT00220220
- Testing
- olmesartan medoxomil, amlodipine
- Where
- 6 sites in Germany
- Volunteers
- 429 people
- Sponsor
- Sankyo Pharma Gmbh
Essential Hypertension
Efficacy and Safety of Levamlodipine Besylate Compared to Amlodipine Maleate in Patients With Essential Hypertension
This study is designed to compare the safety and efficacy of levamlodipine besylate (2.5mg or 5mg) versus amlodipine maleate (5mg) in patients with mild to moderate essential hypertension.
- Trial name
- NCT01131546
- Testing
- Levamlodipine besylate, Amlodipine maleate
- Where
- China
- Volunteers
- 1,080 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Essential Hypertension, Chronic Stable Angina
Observational Study to Evaluate the Safety of DILATREND SR Cap. in Korean Patients With Essential Hypertension, Chronic Stable Angina and Congestive Heart Failure
The purpose of this study is to Evaluate the Safety of DILATREND SR Cap. in Korean Patients with Essential hypertension, Chronic stable angina and Congestive heart failure for 52 weeks.
- Conditions
- Essential Hypertension, Chronic Stable Angina, Congestive Heart Failure
- Trial name
- DELIGHT (NCT03063697)
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Essential Hypertension, Primary Hypercholesterolemia
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1017-1" and Co-administration of "BR1017-1A" and "BR1017-1B"
The objective of this clinical study is to evaluate the pharmacokinetics and the safety after administration of "BR1017-1" and co-administration of "BR1017-1A" and "BR1017-1B" in healthy volunteers
- Trial name
- NCT06184269
- Testing
- BR1017-1, BR1017-1A, BR1017-1B
- Where
- South Korea
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension
S-amlodipine in Essential HypertensIon and Assessment of Blood Pressure Targets Achievement
Evaluate the ratio(%) of patients whose blood pressure measured at 6 months from the baseline was confirmed to be within the target blood pressure range according to the 2022 hypertension treatment guidelines for essential…
- Trial name
- NCT06130124
- Where
- South Korea
- Volunteers
- 5,000 people
- Sponsor
- Hanlim Pharm. Co., Ltd.
Essential Hypertension
Phase IIa Study of the Product QGC001 Compared With Placebo in Patients With Essential Hypertension
2QG1 is a Phase IIa study aiming to assess the blood pressure lowering effect of 4-week administration of QGC001 oral doses in patients with grade I or II essential hypertension compared to placebo, to assess the safety and…
- Trial name
- 2QG1 (NCT02322450)
- Testing
- QGC001
- Where
- 4 sites in France
- Volunteers
- 34 people
- Sponsor
- Quantum Genomics SA
Hypertension
An Examination of the Safety and Blood Pressure Lowering Effect of Increasing Doses of Benicar® and Benicar® HCT in Patients With Hypertension
Effect of increasing doses of olmesartan medoxomil and olmesartan medoxomil/hydrochlorothiazide on blood pressure in patients with hypertension
- Trial name
- NCT00185068
- Testing
- Olmesartan medoxomil, Olmesartan medoxomil/hydrochlorothiazide, Hydrochlorothiazide
- Where
- 16 sites in United States
- Volunteers
- 110 people
- Sponsor
- Daiichi Sankyo
Essential Hypertension
Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension
The primary aim of the study is to assess the antihypertensive efficacy of SPH3127 in patients with mild to moderate essential hypertension.
- Trial name
- NCT05359068
- Testing
- SPH3127 tablet, Valsartan
- Where
- 40 sites in China
- Volunteers
- 957 people
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Hypertension, Essential
A Study to Evaluate the Efficacy and Safety of AD-209
The purpose of this study is to evaluate the efficacy and safety of AD-209
- Trial name
- NCT05631990
- Testing
- AD-209, AD-209-1A, AD-209-1B
- Where
- South Korea
- Volunteers
- 221 people
- Sponsor
- Addpharma Inc.
Essential Hypertension, Metabolic Syndrome
A Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic Syndrome
This is a multi-center, randomized, open-label, active comparator-controlled, phase 4 clinical trial to evaluate the blood pressure control of Telmisartan or Losartan in essential hypertensive patients with metabolic syndrome
- Trial name
- PRISTINE (NCT05843162)
- Testing
- Telmisartan, Losartan
- Volunteers
- 116 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypertension, Isolated Systolic Hypertension (ISH)
A Single Rising Dose Study of MK-8150 (MK-8150-001)
This study will evaluate the safety and tolerability of MK-8150 and its effect on central systolic blood pressure (cSBP) and heart rate corrected augmentation index (AIx) when given as single oral doses in healthy males and in…
- Trial name
- NCT01590810
- Testing
- MK-8150 2.0 mg, MK-8150 10 mg, MK-8150 40 mg
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Essential Hypertension, Hyperlipidemia
Study to Investigate the Effect of Telmisartan/S-amlodipine on the Pharmacokinetic Properties of Atorvastatin.
The purpose of this study is to investigate the effect of telmisartan/s-amlodipine on the pharmacokinetic properties of atorvastatin.
- Trial name
- CKD-345 (NCT01842256)
- Testing
- Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg, atorvastatin 40mg
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Primary Hypertension
Renal Denervation With Sterile Irrigated Deflectable Ablation Catheter Used in Renal Artery in Primary Hypertension
The purpose of this study is to assess the safety and efficacy of renal denervation with sterile irrigated deflectable ablation catheter used in renal artery in primary hypertension in China.
- Trial name
- NCT03511313
- Testing
- Renal denervation, Renal angiography
- Where
- China
- Volunteers
- 264 people
- Sponsor
- Synaptic Medical Corporation
Hypertension
Safety and Efficacy of Valsartan Plus Hydrochlorothiazide and Amlodipine in Hypertensive Patients
A double-blind, active-controlled, randomized trial to compare Valsartan plus Hydrochlorothiazide 80mg/12.5mg and Amlodipine 5 mg. Study design: 2 weeks washout, 8 weeks treatment period.
- Trial name
- NCT00426478
- Testing
- Valsartan plus Hydrochlorothiazide (80mg/12.5mg), Amlodipine (5mg)
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- Novartis
Hypertension
Long Term Study of Valsartan and Amlodipine in Patients With Essential Hypertension (Extension to Study CVAA489A1301)
The purpose of this study is to evaluate long-term safety and tolerability of once daily administration of the combination of Valsartan and Amlodipine 80/5 mg for 52 weeks in patients with essential hypertension.
- Trial name
- NCT00446524
- Testing
- Valsartan + Amlodipine besilate
- Where
- Japan
- Volunteers
- 403 people
- Sponsor
- Novartis
Hypertension
An Extension Trial of GW 906 in Participants With Essential Hypertension
This clinical study was designed to assess the safety and efficacy of long-term dosing of GW906
- Trial name
- NCT07879755
- Testing
- GW906
- Where
- China
- Volunteers
- 1,500 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.